Navigation Links
TriLink BioTechnologies, Inc. Awarded European Patent for CleanAmp™ Primers
Date:5/27/2011

SAN DIEGO, May 27, 2011 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink), a leader in manufacturing high quality oligonucleotides and nucleoside triphosphates, announced today the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).

First launched in March of 2008, CleanAmp™ Primers pioneered TriLink's CleanAmp™ line of next generation Hot Start PCR products. The technology consists of thermolabile chemical modifications which allow for primer-based Hot Start activation in PCR. These modifications prevent primer extension at the lower temperatures of PCR set up and manipulation, eliminating primer dimer and mis-priming events. The performance of CleanAmp™ Primers can be applied to critical applications such as molecular diagnostics, forensics, detection of infectious agents and gene expression validation.

TriLink sought patent protection in Europe in 2007, filing the patent application titled Chemically Modified Oligonucleotide Primers for Nucleic Acid Amplification with the European Patent Office (EPO), under the patent application number 0777161.6, now EPO Patent no. 2032714, published on March 16, 2011.

Gerald Zon, co-inventor, commented, "CleanAmp™ Primers provide flexibility for use with either low-cost polymerases, or to further enhance performance of other PCR components, such as Hot Start polymerases or TriLink's CleanAmp™ dNTPs, in especially demanding applications."

"The CleanAmp™ Primers are the foundation of the CleanAmp™ product line, and paved the way for the innovative solutions of CleanAmp™ dNTPs and CleanAmp™ 7-deaza-dGTP. They continue to inspire us as we apply our nucleic acid chemistry expertise to build unique molecular biology tools," stated Richard Hogrefe, CEO of TriLink.

About TriLink

TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 85 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at www.trilinkbiotech.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
2. TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
3. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
4. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
5. CVS Caremark Awarded Integrated 3-Year Blue Cross and Blue Shield Federal Employee Program (FEP) Contract
6. Awarepoint Awarded U.S. Patent for its Revolutionary Tag-to-Tag Communication Technology
7. Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
8. Brio Device Awarded Best of Ann Arbor SPARKs Boot Camp
9. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
10. MedQuist Awarded Clinical Documentation Outsource Contract for St. Josephs Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind
11. The Female Health Companys Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):